Monte Rosa Therapeutics' stock falls as MRT-2359 faces challenges in targeting CRPC. Click here to read an analysis of GLUE ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

Zytiga sales have been romping away of late in part because of the results of the LATITUDE study in metastatic high-risk castration sensitive prostate cancer, which firmed up its competitive ...

Approval of the drug for men with prostate cancer that has spread but has not yet become hormone resistant, would step up pressure on rival therapy Zytiga (abiraterone acetate) from Johnson ...